Drug Trial Radar · NCT05626959
Evaluating the Efficacy of NTI164 in Young People With Autism Spectrum Disorder
Last checked: Nov 19, 2026Latest source record: Sep 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
54
Actual
Start
Nov 30, 2022
Primary completion
Mar 1, 2024
Study completion May 30, 2026
Sponsor
- Lead sponsor
- Fenix Innovation GroupIndustry
- Sponsor type
- Industry
- Collaborators
- Neurotech International Limited; Monash Health
- First posted
- Nov 25, 2022
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 8 years, up to 17 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is an 18 to 54 week study assessing the efficacy of Full-Spectrum Medicinal Cannabis Plant Extract 0.08% THC (NTI164) on the severity of autism spectrum disorder in young people.
Conditions
- Autism Spectrum Disorder
Interventions
NTI164Drug
Oil based. Full-spectrum medicinal cannabis plant extract with less than 0.08% THC.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in Clinical Global Impression-Severity (CGI-S)Time frame: Baseline, Week 8.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Monash Children's Hospital
Clayton, Victoria, Australia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.